482 related articles for article (PubMed ID: 32895900)
1. Mesenchymal Stromal Cells in Viral Infections: Implications for COVID-19.
Rocha JLM; de Oliveira WCF; Noronha NC; Dos Santos NCD; Covas DT; Picanço-Castro V; Swiech K; Malmegrim KCR
Stem Cell Rev Rep; 2021 Feb; 17(1):71-93. PubMed ID: 32895900
[TBL] [Abstract][Full Text] [Related]
2. Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID-19.
Yen BL; Yen ML; Wang LT; Liu KJ; Sytwu HK
Stem Cells Transl Med; 2020 Oct; 9(10):1163-1173. PubMed ID: 32526079
[TBL] [Abstract][Full Text] [Related]
3. Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential.
Gorman E; Millar J; McAuley D; O'Kane C
Expert Rev Respir Med; 2021 Mar; 15(3):301-324. PubMed ID: 33172313
[No Abstract] [Full Text] [Related]
4. Review of Trials Currently Testing Stem Cells for Treatment of Respiratory Diseases: Facts Known to Date and Possible Applications to COVID-19.
Majolo F; da Silva GL; Vieira L; Timmers LFSM; Laufer S; Goettert MI
Stem Cell Rev Rep; 2021 Feb; 17(1):44-55. PubMed ID: 32827081
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 and its Therapeutics: Special Emphasis on Mesenchymal Stem Cells Based Therapy.
Verma YK; Verma R; Tyagi N; Behl A; Kumar S; Gangenahalli GU
Stem Cell Rev Rep; 2021 Feb; 17(1):113-131. PubMed ID: 32920752
[TBL] [Abstract][Full Text] [Related]
6. The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect.
Can A; Coskun H
Stem Cells Transl Med; 2020 Nov; 9(11):1287-1302. PubMed ID: 32779878
[TBL] [Abstract][Full Text] [Related]
7. Mesenchymal stromal cells to fight SARS-CoV-2: Taking advantage of a pleiotropic therapy.
Barros I; Silva A; de Almeida LP; Miranda CO
Cytokine Growth Factor Rev; 2021 Apr; 58():114-133. PubMed ID: 33397585
[TBL] [Abstract][Full Text] [Related]
8. Mesenchymal Stromal Cell-Based Therapy: A Promising Approach for Severe COVID-19.
Xiong J; Chen L; Zhang L; Bao L; Shi Y
Cell Transplant; 2021; 30():963689721995455. PubMed ID: 33650894
[TBL] [Abstract][Full Text] [Related]
9. Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients.
Rogers CJ; Harman RJ; Bunnell BA; Schreiber MA; Xiang C; Wang FS; Santidrian AF; Minev BR
J Transl Med; 2020 May; 18(1):203. PubMed ID: 32423449
[TBL] [Abstract][Full Text] [Related]
10. Proposed Mechanisms of Targeting COVID-19 by Delivering Mesenchymal Stem Cells and Their Exosomes to Damaged Organs.
Jamshidi E; Babajani A; Soltani P; Niknejad H
Stem Cell Rev Rep; 2021 Feb; 17(1):176-192. PubMed ID: 33432484
[TBL] [Abstract][Full Text] [Related]
11. Mesenchymal stromal/stem cells (MSCs) and MSC-derived extracellular vesicles in COVID-19-induced ARDS: Mechanisms of action, research progress, challenges, and opportunities.
Moradinasab S; Pourbagheri-Sigaroodi A; Zafari P; Ghaffari SH; Bashash D
Int Immunopharmacol; 2021 Aug; 97():107694. PubMed ID: 33932694
[TBL] [Abstract][Full Text] [Related]
12. Mesenchymal stem cells: Biological characteristics and application in disease therapy.
Lou S; Duan Y; Nie H; Cui X; Du J; Yao Y
Biochimie; 2021 Jun; 185():9-21. PubMed ID: 33711361
[TBL] [Abstract][Full Text] [Related]
13. Medical progress: Stem cells as a new therapeutic strategy for COVID-19.
Musial C; Gorska-Ponikowska M
Stem Cell Res; 2021 Apr; 52():102239. PubMed ID: 33601098
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulation and Regeneration Properties of Dental Pulp Stem Cells: A Potential Therapy to Treat Coronavirus Disease 2019.
Zayed M; Iohara K
Cell Transplant; 2020; 29():963689720952089. PubMed ID: 32830527
[TBL] [Abstract][Full Text] [Related]
15. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.
Hashemian SR; Aliannejad R; Zarrabi M; Soleimani M; Vosough M; Hosseini SE; Hossieni H; Keshel SH; Naderpour Z; Hajizadeh-Saffar E; Shajareh E; Jamaati H; Soufi-Zomorrod M; Khavandgar N; Alemi H; Karimi A; Pak N; Rouzbahani NH; Nouri M; Sorouri M; Kashani L; Madani H; Aghdami N; Vasei M; Baharvand H
Stem Cell Res Ther; 2021 Jan; 12(1):91. PubMed ID: 33514427
[TBL] [Abstract][Full Text] [Related]
16. Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders.
Markov A; Thangavelu L; Aravindhan S; Zekiy AO; Jarahian M; Chartrand MS; Pathak Y; Marofi F; Shamlou S; Hassanzadeh A
Stem Cell Res Ther; 2021 Mar; 12(1):192. PubMed ID: 33736695
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal Stem Cell Therapy for COVID-19: Present or Future.
Golchin A; Seyedjafari E; Ardeshirylajimi A
Stem Cell Rev Rep; 2020 Jun; 16(3):427-433. PubMed ID: 32281052
[TBL] [Abstract][Full Text] [Related]
18. Mesenchymal Stem Cells as a Treatment Strategy for Coronavirus Disease 2019 (COVID-19): Need for Authority Regulations and Clinical Guidelines.
Tufan AC
Curr Stem Cell Res Ther; 2021; 16(4):465-480. PubMed ID: 33238848
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal Stem Cells Therapy for COVID-19: From Basic Research to Clinical Trial.
Tao YC; Chen EQ
Curr Stem Cell Res Ther; 2024; 19(1):55-62. PubMed ID: 36654468
[TBL] [Abstract][Full Text] [Related]
20. Systematic review and meta-analysis of cell therapy for COVID-19: global clinical trial landscape, published safety/efficacy outcomes, cell product manufacturing and clinical delivery.
Couto PS; Al-Arawe N; Filgueiras IS; Fonseca DLM; Hinterseher I; Catar RA; Chinnadurai R; Bersenev A; Cabral-Marques O; Moll G; Verter F
Front Immunol; 2023; 14():1200180. PubMed ID: 37415976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
